MCID: CHR562
MIFTS: 38

Chronic Myelocytic Leukemia

Categories: Genetic diseases, Cancer diseases, Rare diseases, Immune diseases

Aliases & Classifications for Chronic Myelocytic Leukemia

MalaCards integrated aliases for Chronic Myelocytic Leukemia:

Name: Chronic Myelocytic Leukemia 24
Myeloid Leukemia, Chronic 69
Cml 24

Classifications:



Summaries for Chronic Myelocytic Leukemia

MalaCards based summary : Chronic Myelocytic Leukemia, also known as myeloid leukemia, chronic, is related to acute myocardial infarction and familial chronic myelocytic leukemia-like syndrome, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Chronic Myelocytic Leukemia is BCR (BCR, RhoGEF And GTPase Activating Protein), and among its related pathways/superpathways are Pathways in cancer and G-protein signaling_Regulation of CDC42 activity. The drugs Dasatinib and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are cellular and immune system

Related Diseases for Chronic Myelocytic Leukemia

Diseases in the Chronic Myelocytic Leukemia family:

Familial Chronic Myelocytic Leukemia-Like Syndrome

Diseases related to Chronic Myelocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 34)
id Related Disease Score Top Affiliating Genes
1 acute myocardial infarction 28.9 BCR RUNX1 TYMS
2 familial chronic myelocytic leukemia-like syndrome 12.3
3 leukemia, chronic myeloid, somatic 11.1
4 leukemia 10.7
5 arteriolosclerosis 10.1 ASS1 TYMS
6 acute monocytic leukemia 10.0 RUNX1 TYMS
7 lymphoma, small cleaved-cell, diffuse 10.0 BCR RUNX1
8 large cell carcinoma with rhabdoid phenotype 9.9 ASS1 TYMS
9 gallbladder cancer 9.9 CASP3 TYMS
10 acute lymphocytic leukemia 9.9
11 cask-related intellectual disability 9.9 BCR RUNX1
12 preeclampsia/eclampsia 3 9.8 BCR RUNX1
13 monoclonal paraproteinemia 9.8 CASP3 TYMS
14 myocardial infarction 9.8
15 myelodysplastic syndrome 9.8
16 lymphoma 9.8
17 lymphoblastic leukemia 9.8
18 pericardial effusion 9.8
19 hereditary spherocytosis 9.8
20 cryoglobulinemia 9.8
21 central nervous system disease 9.8
22 tuberculosis 9.8
23 nervous system disease 9.8
24 myeloid leukemia 9.8
25 bone marrow necrosis 9.8
26 type 2a von willebrand disease 9.8
27 gastric cancer, somatic 9.7 CASP3 RUNX1 TYMS
28 peroxisome biogenesis disorder 7a 9.6 BCR CASP3 RUNX1
29 cranioectodermal dysplasia 1 9.5 BCR CASP3 RUNX1
30 peroxisome biogenesis disorder 5a 9.4 BCR RUNX1 TYMS
31 hemolytic anemia 9.4 BCR RUNX1
32 basilar artery insufficiency 9.4 BCR EPOR
33 nelson syndrome 9.2 BCR EPOR RUNX1
34 col12a1-related muscle diseases 7.8 ASS1 BCR CASP3 EPOR RUNX1 TYMS

Graphical network of the top 20 diseases related to Chronic Myelocytic Leukemia:



Diseases related to Chronic Myelocytic Leukemia

Symptoms & Phenotypes for Chronic Myelocytic Leukemia

UMLS symptoms related to Chronic Myelocytic Leukemia:


angina pectoris, chest pain, edema

MGI Mouse Phenotypes related to Chronic Myelocytic Leukemia:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.55 ASS1 BCR CASP3 EPOR RUNX1
2 immune system MP:0005387 9.35 ASS1 BCR CASP3 EPOR RUNX1
3 nervous system MP:0003631 9.02 ASS1 BCR CASP3 EPOR RUNX1

Drugs & Therapeutics for Chronic Myelocytic Leukemia

Drugs for Chronic Myelocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 496)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dasatinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 302962-49-8 3062316
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
3
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1 135968-09-1
4 Thiotepa Approved Phase 4,Phase 3,Phase 2,Phase 1 52-24-4 5453
5
Benzocaine Approved Phase 4,Phase 2,Phase 3,Phase 1 1994-09-7, 94-09-7 2337
6 tannic acid Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1
7
Lactitol Investigational Phase 4,Phase 2,Phase 3,Phase 1 585-86-4 3871
8 Imatinib Mesylate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 123596
9 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
10 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
11 Hormones Phase 4,Phase 3,Phase 2,Phase 1
12 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
13 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
14 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
15 Interferon-alpha Phase 4,Phase 3,Phase 2,Phase 1
16 interferons Phase 4,Phase 3,Phase 2,Phase 1
17 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1
18 Antilymphocyte Serum Phase 4,Phase 3,Phase 2,Phase 1
19 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
20 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Tin Fluorides Phase 4,Phase 3,Phase 2,Phase 1
22 tyrosine Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1
23
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1 147-94-4 6253
24
Hydroxyurea Approved Phase 3,Phase 2,Phase 1 127-07-1 3657
25
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1 55-98-1 2478
26
Idarubicin Approved Phase 3,Phase 2,Phase 1 58957-92-9 42890
27
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
28
Fludarabine Approved Phase 2, Phase 3, Phase 1 21679-14-1, 75607-67-9 30751
29
Iron Approved Phase 2, Phase 3,Phase 1 7439-89-6 23925
30
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
31
Cefepime Approved Phase 3,Phase 1 88040-23-7 5479537
32
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
33
Ofloxacin Approved Phase 3 82419-36-1 4583
34
Melphalan Approved Phase 3,Phase 2,Phase 1 148-82-3 4053 460612
35
Azacitidine Approved, Investigational Phase 3,Phase 2,Phase 1 320-67-2 9444
36
Decitabine Approved, Investigational Phase 3,Phase 2,Phase 1 2353-33-5 451668
37
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
38
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
39
Peginterferon alfa-2b Approved Phase 3,Phase 2,Phase 1 99210-65-8, 215647-85-1
40
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1 65271-80-9 4212
41
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
42
Tacrolimus Approved, Investigational Phase 3,Phase 2,Phase 1 104987-11-3 445643 439492
43
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2,Phase 1 128794-94-5 5281078
44
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1 24280-93-1 446541
45
Vidarabine Approved Phase 3,Phase 2,Phase 1 24356-66-9 32326 21704
46
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3, Phase 1 83-43-2 6741
47
Prednisolone Approved, Vet_approved Phase 2, Phase 3, Phase 1 50-24-8 5755
48
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 498142 38904
49
ponatinib Approved Phase 3,Phase 2,Phase 1 943319-70-8 24826799
50
Panobinostat Approved, Investigational Phase 2, Phase 3, Phase 1 404950-80-7 6918837

Interventional clinical trials:

(show top 50) (show all 1211)

id Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia Unknown status NCT02317159 Phase 4 Imatinib
2 Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation Unknown status NCT01243489 Phase 4
3 Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Unknown status NCT01901666 Phase 4 Growth Hormone
4 Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response Completed NCT01043874 Phase 4 Nilotinib
5 Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia Completed NCT00390897 Phase 4 Glivec;Interferon
6 Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial Completed NCT01368523 Phase 4 nilotinib
7 Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib Completed NCT00644878 Phase 4 Nilotinib
8 Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Completed NCT00786812 Phase 4 Nilotinib
9 Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib Completed NCT01660906 Phase 4 Dasatinib
10 An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment Completed NCT00980018 Phase 4 Nilotinib
11 Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) Completed NCT00171899 Phase 4 imatinib mesylate
12 Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Completed NCT00081926 Phase 4 Gleevec
13 CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib Completed NCT01227577 Phase 4 Nilotinib
14 Glivec in Pediatric Chronic Myeloid Leukemia (CML) Completed NCT00845221 Phase 4 Imatinib mesylate 100 mg (Glivec)
15 Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase Completed NCT01061177 Phase 4 Nilotinib
16 Tasigna in Glivec-resistant or Intolerant Patients in CML Completed NCT01206088 Phase 4 nilotinib
17 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
18 Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Dasatinib Recruiting NCT02689440 Phase 4 Dasatinib
19 Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia Recruiting NCT03216070 Phase 4 Dasatinib 50 MG
20 Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia Recruiting NCT02602314 Phase 4 Imatinib;Nilotinib
21 Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline. Recruiting NCT02546674 Phase 4 Nilotinib
22 Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors Active, not recruiting NCT02228382 Phase 4 Bosutinib
23 A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients Active, not recruiting NCT02204722 Phase 4 600mg/day of Imatinib;400mg/day of Imatinib
24 Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients Active, not recruiting NCT01578213 Phase 4 Imatinib mesylate
25 Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib Not yet recruiting NCT02389920 Phase 4 Nilotinib
26 Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on Imatinib Terminated NCT00461929 Phase 4
27 Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations Terminated NCT01131325 Phase 4 nilotinib
28 Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib Therapy Terminated NCT02086487 Phase 4 Nilotinib 300 mg.
29 Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase. Withdrawn NCT01605981 Phase 4 AMN107
30 Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Unknown status NCT00055874 Phase 3 cytarabine;hydroxyurea;imatinib mesylate
31 Interferon Alfa in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia Unknown status NCT00002869 Phase 3 cytarabine;hydroxyurea
32 Chemotherapy, Interferon, and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia Unknown status NCT00002771 Phase 3 busulfan;cytarabine;hydroxyurea;idarubicin
33 Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia Unknown status NCT00025402 Phase 3 busulfan;cyclophosphamide;cytarabine;etoposide;hydroxyurea;idarubicin
34 Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia Unknown status NCT01460693 Phase 3 Imatinib;Dasatinib
35 Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase Unknown status NCT00327262 Phase 3 Imatinib
36 Allogeneic Stem Cell Transplantation in CML With Partial T Cell Depletion Unknown status NCT00966810 Phase 2, Phase 3
37 The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CML Unknown status NCT02204644 Phase 3 Flumatinib 600mg qd;Imatinib 400mg qd
38 Efficacy of Nilotinib Versus Imatinib in Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to Imatinib Unknown status NCT01400074 Phase 3 Nilotinib, Imatinib
39 Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy Unknown status NCT00297570 Phase 3 Pegylated Interferon and Imatinib
40 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
41 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
42 Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome Unknown status NCT00047268 Phase 3 cytarabine;mercaptopurine
43 Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation Unknown status NCT01217723 Phase 3
44 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
45 Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome Unknown status NCT00043134 Phase 3 decitabine
46 Efficacy and Safety of LBH589 in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Chronic Phase Completed NCT00451035 Phase 2, Phase 3 LBH589
47 Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients Completed NCT01254188 Phase 3 Nilotinib
48 Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia Completed NCT00333840 Phase 3 imatinib mesilate;interferon-alpha (INF-a);cytarabine (ARA-C)
49 Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase) Completed NCT00237120 Phase 3 Imatinib
50 Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML Completed NCT00123474 Phase 3 dasatinib;dasatinib;dasatinib;dasatinib

Search NIH Clinical Center for Chronic Myelocytic Leukemia

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Chronic Myelocytic Leukemia

Genetic tests related to Chronic Myelocytic Leukemia:

id Genetic test Affiliating Genes
1 Chronic Myelocytic Leukemia 24 BCR

Anatomical Context for Chronic Myelocytic Leukemia

MalaCards organs/tissues related to Chronic Myelocytic Leukemia:

39
Myeloid, Bone, Bone Marrow, T Cells, Kidney, Nk Cells, Breast

Publications for Chronic Myelocytic Leukemia

Articles related to Chronic Myelocytic Leukemia:

(show top 50) (show all 63)
id Title Authors Year
1
Imatinib mesylate- and dasatinib-induced eosinophilia in a patient with chronic myelocytic leukemia. ( 28499700 )
2017
2
Emodin Exerts an Antiapoptotic Effect on Human Chronic Myelocytic Leukemia K562 Cell Lines by Targeting the PTEN/PI3K-AKT Signaling Pathway and Deleting BCR-ABL. ( 27698265 )
2016
3
Upregulation of miR-181c inhibits chemoresistance by targeting ST8SIA4 in chronic myelocytic leukemia. ( 27527856 )
2016
4
A case report of hereditary spherocytosis with concomitant chronic myelocytic leukemia. ( 28352784 )
2016
5
Chronic Myelocytic Leukemia (CML) Patient-Derived Dendritic Cells Transfected with Autologous Total RNA Induces CML-Specific Cytotoxicity. ( 27812247 )
2016
6
Granulocyte colony-stimulating factor-primed bone marrow: an excellent stem-cell source for transplantation in acute myelocytic leukemia and chronic myelocytic leukemia. ( 25563308 )
2015
7
Construction of a protein-protein interaction network for chronic myelocytic leukemia and pathway prediction of molecular complexes. ( 25040996 )
2014
8
Acute pleural and pericardial effusion induced by chemotherapy in treating chronic myelocytic leukemia. ( 24839831 )
2014
9
CIP2A is overexpressed and involved in the pathogenesis of chronic myelocytic leukemia by interacting with breakpoint cluster region-Abelson leukemia virus. ( 25023053 )
2014
10
Population level survival of patients with chronic myelocytic leukemia in Germany compared to the US in the early 21st century. ( 24499592 )
2013
11
Antitumor activity of total paeony glycoside against human chronic myelocytic leukemia K562 cell lines in vitro and in vivo. ( 21452044 )
2012
12
[Effects of hOCT1 and ABCB1 gene on the efficacy of imatinib mesylate in chronic myelocytic leukemia]. ( 22883199 )
2012
13
Correlation between imatinib trough concentration and efficacy in Chinese chronic myelocytic leukemia patients. ( 22473087 )
2012
14
Pretreatment with IFN-I+ increases resistance to imatinib mesylate in patients with chronic myelocytic leukemia. ( 22684027 )
2012
15
Survival of patients with chronic myelocytic leukemia: comparisons of estimates from clinical trial settings and population-based cancer registries. ( 21471276 )
2011
16
Survival more than 19 years after the diagnosis of accelerated phase of chronic myelocytic leukemia. ( 21475132 )
2011
17
Chronic myelocytic leukemia in pregnancy: a case report describing successful treatment using multimodal therapy. ( 21790885 )
2011
18
Non-Hodgkin's lymphoma in a chronic myelocytic leukemia patient treated with imatinib. ( 27264373 )
2011
19
Acute myocardial infarction in a patient with chronic myelocytic leukemia during chemotherapy with hydroxyurea. ( 20721521 )
2010
20
Anti-tumor activity of emodin against human chronic myelocytic leukemia K562 cell lines in vitro and in vivo. ( 19857484 )
2010
21
Extensive cutaneous manifestations: presenting feature of chronic myelocytic leukemia in second blast crisis. ( 21063521 )
2010
22
[Effects of 2-methoxyestradiol on the expression of caspase-3 and survivin in chronic myelocytic leukemia K562 cells]. ( 19379562 )
2009
23
Prevalence of gallstones in patients with chronic myelocytic leukemia. ( 19349718 )
2009
24
Long-term survival in chronic myelocytic leukemia after a first primary malignancy. ( 19272642 )
2009
25
Comparison of the cytogenetic and molecular analyses in the assessment of imatinib response in chronic myelocytic leukemia. ( 19814615 )
2009
26
Dasatinib induces complete cytogenetic response and loss of F359C in an imatinib resistant chronic myelocytic leukemia patient. ( 19391130 )
2009
27
[Effect of PD-L1 blockade on function of dendritic cells derived from chronic myelocytic leukemia]. ( 18928614 )
2008
28
Omacetaxine mepesuccinate--a semisynthetic formulation of the natural antitumoral alkaloid homoharringtonine, for chronic myelocytic leukemia and other myeloid malignancies. ( 18465678 )
2008
29
Recent trends in long-term survival of patients with chronic myelocytic leukemia: disclosing the impact of advances in therapy on the population level. ( 18641022 )
2008
30
Chronic myelocytic leukemia--Part I: History, clinical presentation, and molecular biology. ( 15747785 )
2005
31
[Anti-apoptosis effect of VEGF on the human chronic myelocytic leukemia cell line K562]. ( 16277841 )
2005
32
A novel tricolor, dual-fusion fluorescence in situ hybridization method to detect BCR/ABL fusion in cells with t(9;22)(q34;q11.2) associated with deletion of DNA on the derivative chromosome 9 in chronic myelocytic leukemia. ( 14697634 )
2004
33
Deletion 6p23 and add(11)(p15) leading to NUP98 translocation in a case of therapy-related atypical chronic myelocytic leukemia transforming to acute myelocytic leukemia. ( 15193442 )
2004
34
Massive bone marrow necrosis in a patient with chronic myelocytic leukemia following imatinib mesylate therapy. ( 15377484 )
2004
35
Ph-negative acute lymphocytic leukemia occurring after interferon therapy for Ph-positive chronic myelocytic leukemia. ( 12531230 )
2003
36
Amplification of the BCR/ABL fusion gene clustered on a masked Philadelphia chromosome in a patient with myeloblastic crisis of chronic myelocytic leukemia. ( 12781448 )
2003
37
Chronic myelocytic leukemia with eosinophilia, t(9;12)(q34;p13), and ETV6-ABL gene rearrangement: case report and review of the literature. ( 12505259 )
2002
38
Chronic myelocytic leukemia in a juvenile rhesus macaque (Macaca mulatta). ( 11451396 )
2001
39
Thymidylate synthase activity in leukocytes from patients with chronic myelocytic leukemia and acute lymphocytic leukemia and its inhibition by phenanthroindolizidine alkaloids pergularinine and tylophorinidine. ( 9683281 )
1998
40
Abnormal immunological response to Mycobacterium tuberculosis antigens in a patient with chronic myelocytic leukemia and active tuberculosis. ( 10028542 )
1998
41
Molecular mechanism of blastic crisis in chronic myelocytic leukemia. ( 9209439 )
1997
42
Mutations of the RAS genes in childhood acute myeloid leukemia, myelodysplastic syndrome and juvenile chronic myelocytic leukemia. ( 9379676 )
1997
43
Thrombotic microangiopathy associated with alpha-interferon therapy for chronic myelocytic leukemia. ( 9214412 )
1997
44
Acquired type 2A von Willebrand disease in chronic myelocytic leukemia. ( 8878731 )
1996
45
Increased Evi-1 expression is frequently observed in blastic crisis of chronic myelocytic leukemia. ( 8656673 )
1996
46
Constitutive expression of GATA-1, EPOR, alpha-globin, and gamma-globin genes in myeloid clonogenic cells from juvenile chronic myelocytic leukemia. ( 7795240 )
1995
47
Chronic myelocytic leukemia patients achieving complete cytogenetic conversion under interferon alpha therapy: minimal residual disease follow-up. ( 8609718 )
1995
48
Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia. ( 8313895 )
1994
49
A multicentric randomised study of alpha 2b interferon (IFN) and hydroxyurea (HU) with or without cytosine-arabinoside (Ara-c) in previously untreated patients with Ph+ chronic myelocytic leukemia (CML): preliminary cytogenetic results. ( 8251893 )
1993
50
Rearrangement of retinoic acid receptor alpha and PML in promyelocytic blast crisis of Ph1 chromosome positive chronic myelocytic leukemia with normal copies of chromosome 15. ( 8386953 )
1993

Variations for Chronic Myelocytic Leukemia

Expression for Chronic Myelocytic Leukemia

Search GEO for disease gene expression data for Chronic Myelocytic Leukemia.

Pathways for Chronic Myelocytic Leukemia

Pathways related to Chronic Myelocytic Leukemia according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.73 BCR CASP3 RUNX1
2 10.13 BCR CASP3

GO Terms for Chronic Myelocytic Leukemia

Biological processes related to Chronic Myelocytic Leukemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 response to organic cyclic compound GO:0014070 8.96 CASP3 TYMS
2 response to glucocorticoid GO:0051384 8.62 CASP3 TYMS

Sources for Chronic Myelocytic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....